Non-exclusive drug discount agreement for Epoetin alfa and zeta
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Epoetin alfa und Epoetin zeta (ATC-Code nach WHO: B03XA01)
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
Actual purchase volumes are unknown and depend on prescription behavior, patient count, and pharmacy stockpiling. No mi...
The buyer reserves the right to terminate the open-house procedure early if exclusive discount agreements are signed. H...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Sep 30, 2027
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Sep 2027
- Supply of Epoetin alfa and Epoetin zeta pharmaceutical products under non-exclusive discount agreements
- Open-House model allowing continuous participation by qualified pharmaceutical companies
Show full summary
Non-exclusive drug discount agreement (Open-House model) for Epoetin alfa and zeta (ATC B03XA01) with AOK PLUS. No estimated value, no minimum volumes, and no exclusivity. Participation open continuously until 30 Sep 2027. Strict confidentiality and electronic submission via DTVP portal.
Risks
Actual purchase volumes are unknown and depend on prescription behavior, patient count, and pharmacy stockpiling. No mi...
The buyer reserves the right to terminate the open-house procedure early if exclusive discount agreements are signed. H...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Participants must be pharmaceutical entrepreneurs as defined in §4 Abs. 18 AMG
Administrative
- Submit participation documents via DTVP portal; confidentiality obligations apply
- First submission deadline: 30 April 2026; thereafter according to published schedule
Requirements may be incomplete.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive drug discount agreement for Epoetin alfa and zeta
Open-House model for concluding non-exclusive discount agreements under §130a Abs. 8 SGB V for the active substances Epoetin alfa and Epoetin zeta (ATC B03XA01). No exclusive supply, no guaranteed volumes. Performance in Saxony and Thuringia, Germany.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Epoetin alfa und Epoetin zeta (ATC-Code nach WHO: B03XA01)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 07 Apr 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 236720-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
Actual purchase volumes are unknown and depend on prescription behavior, patient count, and pharmacy stockpiling. No mi...
The buyer reserves the right to terminate the open-house procedure early if exclusive discount agreements are signed. H...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications